Mainz Biomed BV
Mainz Biomed N.V. develops and sells in-vitro diagnostic (IVD) tests for the early detection of cancer in the United States and Europe. It offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. The company also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. In addition, it operates a clinical diagnostic laboratory; and distributes … Read more
Mainz Biomed BV (MYNZ) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: -2.583x
Based on the latest financial reports, Mainz Biomed BV (MYNZ) has a cash flow conversion efficiency ratio of -2.583x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-6.52 Million) by net assets ($2.52 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Mainz Biomed BV - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Mainz Biomed BV's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Mainz Biomed BV Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Mainz Biomed BV ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
ACKERMANS - Dusseldorf Stock Exchang
DU:B3K
|
N/A |
|
Global Sweeteners Holdings Limited
F:3GS
|
0.035x |
|
HG Holdings Inc
OTCQB:STLY
|
0.008x |
|
OMG Group Ltd
AU:OMG
|
-0.341x |
|
Trench Metals Corp
V:TMC
|
-0.087x |
|
Hunter Capital AB (publ)
F:2DD0
|
N/A |
|
FBS Global Limited Ordinary Shares
NASDAQ:FBGL
|
N/A |
|
WIMFARM S.A. EO 1-
F:6WW
|
N/A |
Annual Cash Flow Conversion Efficiency for Mainz Biomed BV (2019–2024)
The table below shows the annual cash flow conversion efficiency of Mainz Biomed BV from 2019 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $6.05 Million | $-17.09 Million | -2.826x | +58.14% |
| 2023-12-31 | $3.25 Million | $-21.94 Million | -6.752x | -544.41% |
| 2022-12-31 | $14.10 Million | $-14.77 Million | -1.048x | -106.97% |
| 2021-12-31 | $6.36 Million | $-3.22 Million | -0.506x | -396.10% |
| 2020-12-31 | $-2.74 Million | $-468.74K | 0.171x | -19.94% |
| 2019-12-31 | $-1.95 Million | $-416.50K | 0.214x | -- |